Pamela Zeitlin
Concepts (482)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | 45 | 2022 | 326 | 6.930 |
Why?
| | Cystic Fibrosis | 68 | 2022 | 1108 | 6.010 |
Why?
| | Chlorides | 11 | 2020 | 136 | 1.530 |
Why?
| | Chloride Channels | 12 | 2013 | 35 | 1.510 |
Why?
| | Benzodioxoles | 6 | 2022 | 115 | 1.170 |
Why?
| | Bronchi | 9 | 2012 | 260 | 1.060 |
Why?
| | Epithelial Cells | 13 | 2024 | 1094 | 1.040 |
Why?
| | Mutation | 18 | 2022 | 3947 | 0.980 |
Why?
| | Nasal Mucosa | 11 | 2024 | 107 | 0.950 |
Why?
| | Interleukin-8 | 8 | 2017 | 268 | 0.830 |
Why?
| | Phenylbutyrates | 5 | 2006 | 23 | 0.770 |
Why?
| | Indoles | 3 | 2022 | 410 | 0.720 |
Why?
| | Alprostadil | 2 | 2013 | 32 | 0.700 |
Why?
| | Aminophenols | 6 | 2022 | 156 | 0.650 |
Why?
| | Respiratory Mucosa | 8 | 2024 | 322 | 0.650 |
Why?
| | Endoplasmic Reticulum | 9 | 2014 | 264 | 0.580 |
Why?
| | Dependovirus | 5 | 2007 | 68 | 0.570 |
Why?
| | Genetic Therapy | 8 | 2011 | 293 | 0.560 |
Why?
| | Digitoxin | 1 | 2017 | 4 | 0.540 |
Why?
| | Pseudomonas Infections | 5 | 2020 | 225 | 0.540 |
Why?
| | Epithelium | 5 | 2021 | 311 | 0.530 |
Why?
| | Ubiquitin | 2 | 2014 | 66 | 0.520 |
Why?
| | Protein Processing, Post-Translational | 3 | 2014 | 465 | 0.500 |
Why?
| | Lung | 11 | 2022 | 4063 | 0.500 |
Why?
| | Mucociliary Clearance | 3 | 2021 | 45 | 0.490 |
Why?
| | Proteomics | 3 | 2012 | 1109 | 0.480 |
Why?
| | Sputum | 10 | 2020 | 311 | 0.470 |
Why?
| | Proteasome Endopeptidase Complex | 3 | 2014 | 155 | 0.470 |
Why?
| | Sp1 Transcription Factor | 2 | 2006 | 24 | 0.460 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 496 | 0.450 |
Why?
| | Ion Transport | 5 | 2020 | 60 | 0.410 |
Why?
| | Scorpion Venoms | 1 | 2013 | 2 | 0.410 |
Why?
| | Gene Expression Regulation | 7 | 2009 | 2605 | 0.390 |
Why?
| | Cell Line | 11 | 2014 | 2838 | 0.380 |
Why?
| | Protein Array Analysis | 2 | 2012 | 57 | 0.380 |
Why?
| | Pseudomonas aeruginosa | 4 | 2016 | 352 | 0.380 |
Why?
| | Lysine | 1 | 2014 | 294 | 0.370 |
Why?
| | Lubiprostone | 3 | 2022 | 9 | 0.370 |
Why?
| | Humans | 80 | 2024 | 136803 | 0.360 |
Why?
| | NF-kappa B | 4 | 2009 | 691 | 0.340 |
Why?
| | Inflammation | 3 | 2017 | 2835 | 0.340 |
Why?
| | Respiratory System | 3 | 2022 | 157 | 0.330 |
Why?
| | Quinolones | 4 | 2022 | 137 | 0.330 |
Why?
| | Trachea | 3 | 2008 | 237 | 0.330 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2010 | 47 | 0.320 |
Why?
| | Caveolin 1 | 1 | 2009 | 19 | 0.320 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2006 | 858 | 0.320 |
Why?
| | Aspergillus fumigatus | 1 | 2008 | 26 | 0.300 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 45 | 0.300 |
Why?
| | Endocytosis | 1 | 2009 | 169 | 0.290 |
Why?
| | Dinoprostone | 3 | 2022 | 191 | 0.290 |
Why?
| | Protein Folding | 4 | 2004 | 280 | 0.290 |
Why?
| | Proteome | 4 | 2009 | 472 | 0.280 |
Why?
| | Tamoxifen | 1 | 2008 | 202 | 0.280 |
Why?
| | Calcium | 3 | 2008 | 1197 | 0.280 |
Why?
| | Transcription Factor CHOP | 1 | 2007 | 31 | 0.280 |
Why?
| | Ofloxacin | 1 | 2007 | 24 | 0.270 |
Why?
| | Levofloxacin | 1 | 2007 | 27 | 0.270 |
Why?
| | Drugs, Investigational | 1 | 2007 | 33 | 0.270 |
Why?
| | S-Nitrosoglutathione | 1 | 2006 | 8 | 0.260 |
Why?
| | Mutant Proteins | 1 | 2007 | 101 | 0.260 |
Why?
| | Adolescent | 31 | 2020 | 21385 | 0.260 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2006 | 26 | 0.250 |
Why?
| | Nebulizers and Vaporizers | 2 | 2005 | 86 | 0.250 |
Why?
| | Interleukin-13 | 2 | 2024 | 149 | 0.250 |
Why?
| | Adult | 34 | 2022 | 37643 | 0.250 |
Why?
| | Pneumonia, Bacterial | 1 | 2007 | 116 | 0.250 |
Why?
| | Membrane Potentials | 5 | 2013 | 284 | 0.240 |
Why?
| | Genetic Testing | 1 | 2008 | 453 | 0.240 |
Why?
| | Chloride Channel Agonists | 2 | 2021 | 84 | 0.240 |
Why?
| | Aerosols | 2 | 2005 | 176 | 0.240 |
Why?
| | Sinusitis | 3 | 2020 | 221 | 0.240 |
Why?
| | Positive-Pressure Respiration | 1 | 2005 | 80 | 0.240 |
Why?
| | Water | 1 | 2008 | 457 | 0.230 |
Why?
| | Estradiol | 1 | 2008 | 518 | 0.230 |
Why?
| | Respiratory Function Tests | 6 | 2021 | 595 | 0.230 |
Why?
| | Anti-Bacterial Agents | 6 | 2014 | 1798 | 0.230 |
Why?
| | Proteins | 3 | 2012 | 1009 | 0.230 |
Why?
| | Homeostasis | 1 | 2008 | 619 | 0.230 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1430 | 0.230 |
Why?
| | Pyrrolidines | 2 | 2022 | 80 | 0.220 |
Why?
| | Curcumin | 1 | 2004 | 29 | 0.220 |
Why?
| | Lectins | 1 | 2024 | 49 | 0.220 |
Why?
| | GPI-Linked Proteins | 1 | 2024 | 72 | 0.220 |
Why?
| | Flavonoids | 1 | 2004 | 85 | 0.210 |
Why?
| | Mucin 5AC | 1 | 2024 | 70 | 0.210 |
Why?
| | Mucus | 1 | 2024 | 79 | 0.210 |
Why?
| | Plicamycin | 1 | 2003 | 3 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 2052 | 0.210 |
Why?
| | Genetic Vectors | 5 | 2005 | 317 | 0.200 |
Why?
| | Immunity, Innate | 1 | 2009 | 825 | 0.200 |
Why?
| | Membrane Proteins | 2 | 2006 | 1163 | 0.200 |
Why?
| | Female | 39 | 2020 | 72816 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2018 | 531 | 0.200 |
Why?
| | Amniotic Fluid | 1 | 2003 | 96 | 0.190 |
Why?
| | Signal Transduction | 4 | 2022 | 5077 | 0.190 |
Why?
| | Male | 37 | 2020 | 67330 | 0.190 |
Why?
| | Receptors, Prostaglandin E, EP2 Subtype | 1 | 2022 | 6 | 0.190 |
Why?
| | Peptides, Cyclic | 1 | 2004 | 259 | 0.190 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 613 | 0.190 |
Why?
| | Heterozygote | 2 | 2021 | 293 | 0.190 |
Why?
| | Prostaglandins | 1 | 2022 | 97 | 0.180 |
Why?
| | Biological Transport | 3 | 2008 | 416 | 0.180 |
Why?
| | Animals | 19 | 2022 | 36850 | 0.180 |
Why?
| | Pyrazoles | 2 | 2022 | 423 | 0.180 |
Why?
| | Child | 26 | 2024 | 21819 | 0.180 |
Why?
| | Oxadiazoles | 2 | 2014 | 33 | 0.180 |
Why?
| | Pyridines | 2 | 2022 | 506 | 0.180 |
Why?
| | Epithelial Sodium Channels | 1 | 2021 | 20 | 0.180 |
Why?
| | Aminopyridines | 2 | 2021 | 98 | 0.170 |
Why?
| | Quinolines | 1 | 2021 | 177 | 0.170 |
Why?
| | Nanoparticles | 3 | 2011 | 478 | 0.160 |
Why?
| | Tobramycin | 4 | 2014 | 50 | 0.160 |
Why?
| | Protein Structure, Tertiary | 2 | 2014 | 860 | 0.160 |
Why?
| | Antibodies, Viral | 2 | 2003 | 624 | 0.160 |
Why?
| | Protein Transport | 3 | 2014 | 443 | 0.160 |
Why?
| | Ergocalciferols | 2 | 2010 | 13 | 0.160 |
Why?
| | Paranasal Sinuses | 1 | 2020 | 80 | 0.160 |
Why?
| | Ataxia Telangiectasia | 2 | 2010 | 20 | 0.160 |
Why?
| | Molecular Chaperones | 3 | 2008 | 195 | 0.150 |
Why?
| | Mice | 10 | 2022 | 17759 | 0.150 |
Why?
| | Pulmonary Medicine | 2 | 2010 | 85 | 0.150 |
Why?
| | Double-Blind Method | 6 | 2017 | 1982 | 0.150 |
Why?
| | Cyclic AMP | 3 | 2008 | 234 | 0.150 |
Why?
| | Genotype | 6 | 2021 | 1914 | 0.150 |
Why?
| | Immunoglobulin G | 1 | 2003 | 887 | 0.150 |
Why?
| | Administration, Intranasal | 4 | 2007 | 89 | 0.150 |
Why?
| | Asthma | 2 | 2024 | 2282 | 0.150 |
Why?
| | Subcellular Fractions | 2 | 2008 | 82 | 0.150 |
Why?
| | Sweat | 4 | 2016 | 47 | 0.140 |
Why?
| | Administration, Inhalation | 8 | 2007 | 683 | 0.140 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2020 | 220 | 0.140 |
Why?
| | Cell Membrane | 2 | 2014 | 735 | 0.140 |
Why?
| | Vitamins | 2 | 2010 | 185 | 0.140 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 7 | 0.130 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 27 | 0.130 |
Why?
| | Biomarkers | 4 | 2017 | 4145 | 0.130 |
Why?
| | Respiratory Tract Infections | 3 | 2008 | 394 | 0.130 |
Why?
| | Vitamin D Deficiency | 2 | 2010 | 186 | 0.130 |
Why?
| | Maryland | 1 | 2017 | 59 | 0.130 |
Why?
| | Lung Diseases | 1 | 2003 | 768 | 0.130 |
Why?
| | Rifampin | 1 | 2017 | 84 | 0.130 |
Why?
| | Leukocyte Count | 1 | 2017 | 329 | 0.130 |
Why?
| | Mice, Knockout | 3 | 2009 | 3009 | 0.120 |
Why?
| | Adenosine Triphosphate | 2 | 2008 | 487 | 0.120 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1501 | 0.120 |
Why?
| | Computational Biology | 2 | 2012 | 643 | 0.120 |
Why?
| | Drug Combinations | 3 | 2022 | 343 | 0.120 |
Why?
| | Transcription Factors | 1 | 2003 | 1718 | 0.110 |
Why?
| | Gene Transfer Techniques | 3 | 2005 | 169 | 0.110 |
Why?
| | Young Adult | 9 | 2020 | 13129 | 0.110 |
Why?
| | Cell Line, Transformed | 2 | 2006 | 145 | 0.110 |
Why?
| | Child, Preschool | 11 | 2021 | 10997 | 0.110 |
Why?
| | Drug Design | 2 | 2007 | 167 | 0.110 |
Why?
| | Sodium Chloride | 2 | 2005 | 142 | 0.110 |
Why?
| | Ubiquitination | 1 | 2014 | 102 | 0.110 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 2 | 2016 | 11 | 0.110 |
Why?
| | Amiloride | 2 | 2004 | 26 | 0.110 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2016 | 21 | 0.110 |
Why?
| | Protein Stability | 1 | 2014 | 176 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2021 | 4192 | 0.110 |
Why?
| | Proteolysis | 1 | 2014 | 177 | 0.100 |
Why?
| | Isoproterenol | 2 | 2004 | 113 | 0.100 |
Why?
| | Mass Spectrometry | 2 | 2014 | 738 | 0.100 |
Why?
| | Pediatrics | 3 | 2010 | 1094 | 0.100 |
Why?
| | Sleep | 1 | 2019 | 753 | 0.100 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 1249 | 0.100 |
Why?
| | Phenotype | 6 | 2016 | 3189 | 0.100 |
Why?
| | Neutrophils | 2 | 2017 | 1236 | 0.100 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 3 | 2009 | 114 | 0.100 |
Why?
| | Colforsin | 2 | 2021 | 53 | 0.100 |
Why?
| | RNA, Messenger | 4 | 2008 | 2831 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2006 | 839 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2014 | 729 | 0.090 |
Why?
| | Expectorants | 1 | 2011 | 24 | 0.090 |
Why?
| | Down-Regulation | 3 | 2021 | 656 | 0.090 |
Why?
| | Staining and Labeling | 1 | 2012 | 148 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3286 | 0.090 |
Why?
| | Protein Conformation | 1 | 2014 | 933 | 0.090 |
Why?
| | Transduction, Genetic | 1 | 2011 | 126 | 0.090 |
Why?
| | Research Personnel | 2 | 2010 | 171 | 0.090 |
Why?
| | Mice, Inbred C57BL | 3 | 2013 | 5750 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2011 | 145 | 0.090 |
Why?
| | Vital Capacity | 1 | 2011 | 311 | 0.080 |
Why?
| | Endopeptidases | 1 | 2010 | 90 | 0.080 |
Why?
| | Cervix Mucus | 1 | 2009 | 1 | 0.080 |
Why?
| | Anhydrides | 1 | 2009 | 18 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 762 | 0.080 |
Why?
| | Homozygote | 1 | 2010 | 203 | 0.080 |
Why?
| | Membrane Microdomains | 1 | 2009 | 31 | 0.080 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2009 | 104 | 0.080 |
Why?
| | Posterior Horn Cells | 1 | 2009 | 9 | 0.080 |
Why?
| | Rats | 4 | 2009 | 5639 | 0.080 |
Why?
| | Synaptosomes | 1 | 2009 | 30 | 0.080 |
Why?
| | Models, Biological | 2 | 2007 | 1773 | 0.080 |
Why?
| | Spiperone | 1 | 2008 | 1 | 0.080 |
Why?
| | Models, Molecular | 1 | 2014 | 1570 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 324 | 0.080 |
Why?
| | Nutrition Assessment | 1 | 2009 | 91 | 0.070 |
Why?
| | Electric Conductivity | 1 | 2008 | 86 | 0.070 |
Why?
| | Drug Carriers | 1 | 2009 | 127 | 0.070 |
Why?
| | Respiratory System Agents | 1 | 2008 | 22 | 0.070 |
Why?
| | Endoscopy | 1 | 2011 | 318 | 0.070 |
Why?
| | Ribosomes | 1 | 2010 | 186 | 0.070 |
Why?
| | Administration, Topical | 1 | 2008 | 149 | 0.070 |
Why?
| | Malnutrition | 1 | 2009 | 82 | 0.070 |
Why?
| | Biopsy | 1 | 2012 | 1124 | 0.070 |
Why?
| | Polyethylene Glycols | 2 | 2011 | 640 | 0.070 |
Why?
| | Codon, Terminator | 2 | 2007 | 25 | 0.070 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2007 | 7 | 0.070 |
Why?
| | GTP-Binding Protein alpha Subunits, Gs | 1 | 2007 | 11 | 0.070 |
Why?
| | Blotting, Western | 2 | 2007 | 1225 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2005 | 330 | 0.070 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 431 | 0.070 |
Why?
| | Adenoviridae | 2 | 2005 | 193 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2163 | 0.070 |
Why?
| | Cytosol | 1 | 2008 | 226 | 0.070 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2007 | 138 | 0.070 |
Why?
| | Aminoglycosides | 1 | 2007 | 25 | 0.070 |
Why?
| | Treatment Outcome | 9 | 2018 | 10748 | 0.070 |
Why?
| | Technology, Pharmaceutical | 1 | 2007 | 30 | 0.070 |
Why?
| | Ibuprofen | 1 | 2007 | 84 | 0.070 |
Why?
| | Metabolic Clearance Rate | 1 | 2007 | 115 | 0.070 |
Why?
| | Mannose-Binding Lectin | 1 | 2006 | 23 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2008 | 162 | 0.070 |
Why?
| | Cyclooxygenase 2 | 1 | 2007 | 178 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1282 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2007 | 159 | 0.060 |
Why?
| | Nutritional Status | 1 | 2009 | 344 | 0.060 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2006 | 27 | 0.060 |
Why?
| | DNA Primers | 1 | 2007 | 514 | 0.060 |
Why?
| | Polysaccharide-Lyases | 1 | 2006 | 11 | 0.060 |
Why?
| | Valosin Containing Protein | 1 | 2006 | 5 | 0.060 |
Why?
| | Tunicamycin | 1 | 2006 | 12 | 0.060 |
Why?
| | Proteasome Inhibitors | 1 | 2006 | 46 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2006 | 32 | 0.060 |
Why?
| | DNA, Viral | 2 | 2005 | 363 | 0.060 |
Why?
| | CHO Cells | 1 | 2006 | 161 | 0.060 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2005 | 7 | 0.060 |
Why?
| | Luciferases | 2 | 2003 | 149 | 0.060 |
Why?
| | Gamma Cameras | 1 | 2005 | 8 | 0.060 |
Why?
| | Cricetinae | 1 | 2006 | 289 | 0.060 |
Why?
| | Radionuclide Imaging | 1 | 2005 | 118 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 240 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 151 | 0.060 |
Why?
| | Glutamine | 1 | 2006 | 103 | 0.060 |
Why?
| | Purinergic P2 Receptor Agonists | 1 | 2005 | 6 | 0.060 |
Why?
| | Spinal Cord Injuries | 1 | 2009 | 212 | 0.060 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2005 | 11 | 0.060 |
Why?
| | Uridine | 1 | 2005 | 30 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 975 | 0.060 |
Why?
| | Adenosine Triphosphatases | 1 | 2006 | 165 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 595 | 0.060 |
Why?
| | Precision Medicine | 1 | 2009 | 426 | 0.060 |
Why?
| | Chronic Disease | 2 | 2008 | 1786 | 0.060 |
Why?
| | Radiopharmaceuticals | 1 | 2005 | 177 | 0.060 |
Why?
| | Polymers | 1 | 2009 | 488 | 0.060 |
Why?
| | Acidosis | 1 | 2006 | 101 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1458 | 0.060 |
Why?
| | Gene Expression Profiling | 3 | 2006 | 1772 | 0.050 |
Why?
| | Nasal Polyps | 1 | 2004 | 59 | 0.050 |
Why?
| | Particle Size | 1 | 2005 | 392 | 0.050 |
Why?
| | Inhalation Exposure | 1 | 2004 | 105 | 0.050 |
Why?
| | Base Sequence | 1 | 2007 | 2179 | 0.050 |
Why?
| | Bronchial Provocation Tests | 1 | 2003 | 51 | 0.050 |
Why?
| | Dietary Supplements | 1 | 2008 | 559 | 0.050 |
Why?
| | Transfection | 1 | 2006 | 941 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2010 | 785 | 0.050 |
Why?
| | Sp3 Transcription Factor | 1 | 2003 | 5 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 2 | 2003 | 664 | 0.050 |
Why?
| | Biomedical Research | 1 | 2010 | 688 | 0.050 |
Why?
| | Diuretics | 1 | 2003 | 74 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2004 | 282 | 0.050 |
Why?
| | Heat-Shock Proteins | 1 | 2004 | 142 | 0.050 |
Why?
| | Protein Denaturation | 1 | 2003 | 74 | 0.050 |
Why?
| | Xanthines | 1 | 2002 | 19 | 0.050 |
Why?
| | RNA Interference | 1 | 2005 | 466 | 0.050 |
Why?
| | Isoflavones | 1 | 2002 | 26 | 0.050 |
Why?
| | 5' Flanking Region | 1 | 2002 | 9 | 0.050 |
Why?
| | Clinical Protocols | 1 | 2004 | 267 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 2064 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2002 | 77 | 0.050 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2002 | 89 | 0.050 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 2002 | 150 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2412 | 0.050 |
Why?
| | Disease Progression | 3 | 2017 | 2751 | 0.050 |
Why?
| | Carrier State | 1 | 2002 | 67 | 0.050 |
Why?
| | Dimethyl Sulfoxide | 1 | 2022 | 41 | 0.050 |
Why?
| | 1-Methyl-3-isobutylxanthine | 1 | 2021 | 24 | 0.050 |
Why?
| | Aging | 2 | 2003 | 1864 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2004 | 1044 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2003 | 247 | 0.050 |
Why?
| | Anesthesiologists | 1 | 2022 | 28 | 0.050 |
Why?
| | Forecasting | 1 | 2003 | 388 | 0.050 |
Why?
| | NIH 3T3 Cells | 1 | 2021 | 144 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2003 | 403 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1242 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2005 | 789 | 0.050 |
Why?
| | Patient Acceptance of Health Care | 1 | 2008 | 805 | 0.050 |
Why?
| | Point Mutation | 1 | 2002 | 235 | 0.050 |
Why?
| | Electrophysiology | 1 | 2021 | 217 | 0.040 |
Why?
| | Up-Regulation | 1 | 2004 | 844 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2004 | 1062 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 985 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2006 | 915 | 0.040 |
Why?
| | Infant | 4 | 2020 | 9395 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2024 | 659 | 0.040 |
Why?
| | Codon, Nonsense | 2 | 2014 | 44 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2003 | 254 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2004 | 338 | 0.040 |
Why?
| | Respiration | 1 | 2021 | 199 | 0.040 |
Why?
| | Nasal Surgical Procedures | 1 | 2020 | 6 | 0.040 |
Why?
| | Viscosity | 2 | 2011 | 92 | 0.040 |
Why?
| | Middle Aged | 8 | 2020 | 33239 | 0.040 |
Why?
| | Drug Monitoring | 2 | 2017 | 218 | 0.040 |
Why?
| | Cell Survival | 1 | 2003 | 1116 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 844 | 0.040 |
Why?
| | Patient Care Team | 1 | 2004 | 626 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1455 | 0.040 |
Why?
| | Cytokines | 2 | 2024 | 2084 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2017 | 655 | 0.040 |
Why?
| | Albuterol | 1 | 2019 | 110 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1733 | 0.040 |
Why?
| | Spirometry | 1 | 2019 | 281 | 0.040 |
Why?
| | Haplotypes | 1 | 2020 | 494 | 0.040 |
Why?
| | Biological Products | 1 | 2021 | 215 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2829 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2020 | 15510 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 675 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 6 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 562 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 148 | 0.030 |
Why?
| | Bacteria | 1 | 2003 | 854 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 63 | 0.030 |
Why?
| | Seasons | 2 | 2010 | 544 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2017 | 337 | 0.030 |
Why?
| | Fellowships and Scholarships | 2 | 2010 | 303 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 179 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 407 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2003 | 1982 | 0.030 |
Why?
| | China | 1 | 2016 | 216 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 145 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1022 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2017 | 3540 | 0.030 |
Why?
| | Exons | 1 | 2016 | 351 | 0.030 |
Why?
| | Bronchiectasis | 1 | 2016 | 111 | 0.030 |
Why?
| | Colony Count, Microbial | 2 | 2005 | 120 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1507 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6809 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2005 | 2123 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2007 | 1059 | 0.030 |
Why?
| | Genes, Reporter | 2 | 2005 | 268 | 0.030 |
Why?
| | Prevalence | 2 | 2010 | 2710 | 0.020 |
Why?
| | Polylysine | 1 | 2011 | 17 | 0.020 |
Why?
| | Biopolymers | 1 | 2011 | 31 | 0.020 |
Why?
| | Diffusion | 1 | 2011 | 116 | 0.020 |
Why?
| | Mucins | 1 | 2011 | 73 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2010 | 5106 | 0.020 |
Why?
| | Plasmids | 1 | 2011 | 360 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2010 | 22 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 7 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2009 | 2486 | 0.020 |
Why?
| | Pregnancy | 1 | 2003 | 6729 | 0.020 |
Why?
| | Calcifediol | 1 | 2010 | 33 | 0.020 |
Why?
| | alpha-Fetoproteins | 1 | 2010 | 46 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2668 | 0.020 |
Why?
| | Accreditation | 1 | 2010 | 82 | 0.020 |
Why?
| | Societies, Scientific | 1 | 2009 | 51 | 0.020 |
Why?
| | Immunoassay | 1 | 2010 | 113 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2009 | 11 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2011 | 5424 | 0.020 |
Why?
| | Adhesiveness | 1 | 2009 | 20 | 0.020 |
Why?
| | Mice, Inbred CFTR | 1 | 2008 | 5 | 0.020 |
Why?
| | Cohort Studies | 2 | 2011 | 5704 | 0.020 |
Why?
| | Type C Phospholipases | 1 | 2008 | 74 | 0.020 |
Why?
| | Baltimore | 1 | 2008 | 58 | 0.020 |
Why?
| | Biological Assay | 1 | 2008 | 123 | 0.020 |
Why?
| | Small Molecule Libraries | 1 | 2008 | 94 | 0.020 |
Why?
| | Drug Discovery | 1 | 2008 | 141 | 0.020 |
Why?
| | Cell Polarity | 1 | 2008 | 141 | 0.020 |
Why?
| | Hospitals, University | 1 | 2008 | 182 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 408 | 0.020 |
Why?
| | Career Choice | 1 | 2009 | 216 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 2878 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 384 | 0.020 |
Why?
| | Placebos | 1 | 2007 | 199 | 0.020 |
Why?
| | Solutions | 1 | 2007 | 167 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 382 | 0.020 |
Why?
| | Gentamicins | 1 | 2007 | 54 | 0.020 |
Why?
| | Sulfur Radioisotopes | 1 | 2006 | 15 | 0.020 |
Why?
| | Silver Staining | 1 | 2006 | 17 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 8 | 0.020 |
Why?
| | Dual Oxidases | 1 | 2006 | 4 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2008 | 266 | 0.020 |
Why?
| | Salivary Proteins and Peptides | 1 | 2006 | 14 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7573 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2006 | 64 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 809 | 0.020 |
Why?
| | Comorbidity | 1 | 2011 | 1614 | 0.020 |
Why?
| | Energy Intake | 1 | 2009 | 484 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 144 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2008 | 562 | 0.020 |
Why?
| | Cell Membrane Permeability | 1 | 2006 | 78 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2006 | 113 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2005 | 72 | 0.020 |
Why?
| | Serum | 1 | 2006 | 59 | 0.020 |
Why?
| | Methionine | 1 | 2006 | 160 | 0.020 |
Why?
| | Receptors, Purinergic P2Y2 | 1 | 2005 | 4 | 0.010 |
Why?
| | Helper Viruses | 1 | 2005 | 2 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2008 | 434 | 0.010 |
Why?
| | Burkholderia | 1 | 2005 | 12 | 0.010 |
Why?
| | Societies, Medical | 1 | 2009 | 817 | 0.010 |
Why?
| | Education, Medical, Graduate | 1 | 2010 | 481 | 0.010 |
Why?
| | Severity of Illness Index | 2 | 2004 | 2822 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2005 | 58 | 0.010 |
Why?
| | Nasal Cavity | 1 | 2005 | 52 | 0.010 |
Why?
| | Hemoptysis | 1 | 2005 | 36 | 0.010 |
Why?
| | Peroxidase | 1 | 2005 | 175 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 560 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 888 | 0.010 |
Why?
| | Quality of Health Care | 1 | 2009 | 634 | 0.010 |
Why?
| | Reference Values | 1 | 2006 | 816 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 42 | 0.010 |
Why?
| | Syndrome | 1 | 2004 | 357 | 0.010 |
Why?
| | Siblings | 1 | 2004 | 227 | 0.010 |
Why?
| | Antibodies | 1 | 2006 | 411 | 0.010 |
Why?
| | DNA, Recombinant | 1 | 2003 | 47 | 0.010 |
Why?
| | Treatment Failure | 1 | 2004 | 354 | 0.010 |
Why?
| | Saline Solution, Hypertonic | 1 | 2003 | 41 | 0.010 |
Why?
| | Heating | 1 | 2003 | 23 | 0.010 |
Why?
| | Survival Analysis | 1 | 2006 | 1321 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 1262 | 0.010 |
Why?
| | Virus Shedding | 1 | 2003 | 48 | 0.010 |
Why?
| | Hearing Disorders | 1 | 2002 | 8 | 0.010 |
Why?
| | Probability | 1 | 2004 | 304 | 0.010 |
Why?
| | Survivors | 1 | 2006 | 487 | 0.010 |
Why?
| | Logistic Models | 1 | 2008 | 2067 | 0.010 |
Why?
| | Audiometry | 1 | 2002 | 26 | 0.010 |
Why?
| | Dyspnea | 1 | 2005 | 254 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2004 | 223 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 24 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2003 | 328 | 0.010 |
Why?
| | Oropharynx | 1 | 2002 | 46 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2003 | 412 | 0.010 |
Why?
| | Viremia | 1 | 2003 | 138 | 0.010 |
Why?
| | United States | 2 | 2010 | 14691 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2009 | 1314 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 97 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2002 | 297 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 766 | 0.010 |
Why?
| | Interleukins | 1 | 2003 | 251 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1350 | 0.010 |
Why?
| | Gene Rearrangement | 1 | 2002 | 149 | 0.010 |
Why?
| | Recurrence | 1 | 2004 | 1055 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 4013 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2002 | 399 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 530 | 0.010 |
Why?
| | Pedigree | 1 | 2002 | 514 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1316 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1500 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 851 | 0.010 |
Why?
| | Safety | 1 | 2002 | 338 | 0.010 |
Why?
| | Creatinine | 1 | 2002 | 499 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 778 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 953 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2375 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1936 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1664 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2004 | 951 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2552 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3265 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1322 | 0.010 |
Why?
| | Kidney Diseases | 1 | 2002 | 407 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 4282 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 806 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2010 | 5744 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2008 | 6032 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2002 | 938 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2184 | 0.010 |
Why?
| | Risk Assessment | 1 | 2004 | 3434 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 10332 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2002 | 2489 | 0.000 |
Why?
|
|
Zeitlin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|